Thanks, Acclivity. I was unimpressed by the Sharp appointment - couldn't see what special US expertise or contacts he would bring, and only another director to receive fees - unless one of the others intends to resign .
As to sales - very unlikely to be a significant increase in the quarter just finishing. I am always looking for problems; one possible one might be that the sales for the quarter will be underwhelming , and the costs higher, and disappointed holders might sell .
All the best, Mirri
Ann: ImpediMed Achieves Critical Mass in First Key Target State, page-15
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
